Fluicell AB
The answer first
Does Fluicell beat the market?
Yes, Fluicell has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 90% of Nordic stocks
- Quality98
- Value78
- Trend40
No. 12 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Fluicell keeps shrinks about 7% a year for 10 years.
Max for seven days
Follow Fluicell with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Fluicell
Your first answer is free, no account needed.
Do you own Fluicell, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Fluicell and a few more. Free, no card.
Super Stock+45.9%In short
- Fluicell has risen 79.7% over the past year, including dividends.
- Overall, Fluicell ranks better than 90% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.5%. The price is 99.2% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 90% of Nordic stocks.
No. 12 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 11 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.13
- Asset turnoverSales divided by everything the company owns1.03
- Return on equityProfit divided by equity+31.1%
- Cash conversionOperating cash flow divided by profit1.14
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 13 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity2.0
- P/SPrice divided by sales1.5
- P/EPrice divided by earnings6.3
- P/CFPrice divided by operating cash flow5.8
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 89 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−23.9%
- 6 months−30.7%
- 9 months+142.1%
- 12 months+79.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Fluicell
Fluicell AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.


See the full analysis of Fluicell.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card